Diagnostic and prognostic value of microRNA‑193b in patients with glioma and its effect on tumor progression

Zhu,Mingtao; Zhao,Wei; Zhao,Hui; Zhang,Jing

doi:10.3892/ol.2019.10819

Diagnostic and prognostic value of microRNA‑193b in patients with glioma and its effect on tumor progression

Authors:
- Mingtao Zhu
- Wei Zhao
- Hui Zhao
- Jing Zhang
View Affiliations

Affiliations: Department of Neurosurgery, Xinglin Branch of The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China, Department of Neurosurgery, Heze Municipal Hospital, Heze, Shandong 274031, P.R. China, Department of Pharmacology, Heze Medical College, Heze, Shandong 274000, P.R. China
Published online on: September 6, 2019 https://doi.org/10.3892/ol.2019.10819
Pages: 4882-4890
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emerging evidence has indicated the important roles of microRNAs (miRs) in the pathogenesis of cancer in humans. The present study sought to assess the expression patterns of miR‑193b in patients with glioma, and investigated its clinical significance and biological function in this disease. The expression of miR‑193b in the serum, tissues and cells of patients with glioma was analyzed using reverse transcription‑quantitative PCR. Its diagnostic value was evaluated using the receiver operating characteristic (ROC) curve analysis, and its prognostic value was analyzed using Kaplan‑Meier survival and Cox regression analyses. Experiments on glioma cells were conducted to explore the influence of miR‑193b on proliferation, migration and invasion. Increased expression of miR‑193b was observed in serum, tissues and cells of patients with glioma compared with the corresponding controls (all P<0.05). miR‑193b expression was associated with the World Health Organization grading and the Karnofsky Performance Scale of the patients (all P<0.05). The area under the curve of the ROC analysis of miR‑193b was 0.903, indicating its high diagnostic accuracy for glioma. High expression of miR‑193b was associated with poor overall survival rate in patients (P=0.002). Therefore, miR‑193b is a potential independent prognostic factor in glioma. Furthermore, the overexpression of this miR in glioma cells led to increased proliferation, migration and invasion, whereas its inhibition resulted in the opposite effects on these cell behaviors (all P<0.05). Thus, the findings from the present study indicate that the overexpression of miR‑193b serves as a useful biomarker for the diagnosis and prediction of prognosis in glioma. The upregulation of miR‑193b expression may enhance glioma progression, and may therefore be a potential target for glioma therapy.

View Figures

View References

1	Pastuszak Z, Tomczykiewicz K, Piusinska-Macoch R, Stępień A and Kordowska J: The occurrence of tumors of the central nervous system in a clinical observation. Pol Merkur Lekarski. 38:88–92. 2015.PubMed/NCBI
2	Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG and Visser O; Dutch Society for Neuro-Oncology (LWNO), : Changing incidence and improved survival of gliomas. Eur J Cancer. 50:2309–2318. 2014. View Article : Google Scholar : PubMed/NCBI
3	Malzkorn B and Reifenberger G: Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Curr Opin Oncol. 28:494–501. 2016. View Article : Google Scholar : PubMed/NCBI
4	Olar A and Aldape KD: Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 232:165–177. 2014. View Article : Google Scholar : PubMed/NCBI
5	Huang L, Liu J, Yu X, Shi L, Liu J, Xiao H and Huang Y: Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Biomed Chromatogr. 30:1591–1598. 2016. View Article : Google Scholar : PubMed/NCBI
6	Panditharatna E, Yaeger K, Kilburn LB, Packer R and Nazarian J: Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genet. 208:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
7	Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich JN, Hjelmeland AB and Lathia JD: Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. Neuro Oncol. 17:361–371. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang H, Song X, Huang Q, Xu T, Yun D, Wang Y, Hu L, Yan Y, Chen H, Lu D and Chen J: LGALS3 promotes treatment resistance in glioblastoma and is associated with tumor risk and prognosis. Cancer Epidemiol Biomarkers Prev. 28:760–769. 2019. View Article : Google Scholar : PubMed/NCBI
9	Zhang L, Zhu Y, Cheng H, Zhang J, Zhu Y, Chen H, Chen L, Qi H, Ren G, Tanget J, et al: The increased expression of estrogen related receptor α correlates with wnt5a and poor prognosis in patients with glioma. Mol Cancer Ther. 152018.(18): 173–184, 2019.
10	Wang WT and Chen YQ: Circulating miRNAs in cancer: From detection to therapy. J Hematol Oncol. 7:862014. View Article : Google Scholar : PubMed/NCBI
11	Harrandah AM, Mora RA and Chan EKL: Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. Cancer Lett. 438:126–132. 2018. View Article : Google Scholar : PubMed/NCBI
12	Chen L, Hu J, Pan L, Yin X, Wang Q and Chen H: Diagnostic and prognostic value of serum miR-99a expression in oral squamous cell carcinoma. Cancer Biomark. 23:333–339. 2018. View Article : Google Scholar : PubMed/NCBI
13	Deng YH, Deng ZH, Hao H, Wu XL, Gao H, Tang SH and Tang H: MicroRNA-23a promotes colorectal cancer cell survival by targeting PDK4. Exp Cell Res. 373:171–179. 2018. View Article : Google Scholar : PubMed/NCBI
14	Gao W, Hong Z, Huang H, Zhu A, Lin S, Cheng C, Zhang X, Zou G and Shi Z: miR-27a in serum acts as biomarker for prostate cancer detection and promotes cell proliferation by targeting Sprouty2. Oncol Lett. 16:5291–5298. 2018.PubMed/NCBI
15	Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun TQ, Guan Q and Wang YJ: miR-584 suppresses invasion and cell migration of thyroid carcinoma by regulating the target oncogene ROCK1. Oncol Res Treat. 38:436–440. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kong Q, Han J, Deng H, Wu F, Guo S and Ye Z: miR-431-5p alters the epithelial-to-mesenchymal transition markers by targeting UROC28 in hepatoma cells. Onco Targets Ther. 11:6489–6503. 2018. View Article : Google Scholar : PubMed/NCBI
17	Yin W, Nie Y, Chen L, Wang Q, Liu S, He X and Wang W: Deregulation of microRNA-193b affects the proliferation of liver cancer via myeloid cell leukemia-1. Oncol Lett. 15:2781–2788. 2018.PubMed/NCBI
18	Wang L, Zhang Y, Zhao L, Liu S, Yu S, Ma Y and Sun G: MicroRNA-193b inhibits the proliferation, migration and invasion of gastric cancer cells via targeting cyclin D1. Acta Histochem. 118:323–330. 2016. View Article : Google Scholar : PubMed/NCBI
19	Guo F, Luo Y, Mu YF, Qin SL, Qi Y, Qiu YE and Zhong M: miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer. Am J Cancer Res. 6:2463–2475. 2016.PubMed/NCBI
20	Zhong Q, Wang T, Lu P, Zhang R, Zou J and Yuan S: miR-193b promotes cell proliferation by targeting Smad3 in human glioma. J Neurosci Res. 92:619–626. 2014. View Article : Google Scholar : PubMed/NCBI
21	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ and Thompson RC: The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol. 121:359–364. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
25	Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X and Jiao S: MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 6:25266–25280. 2015. View Article : Google Scholar : PubMed/NCBI
26	Dassow H and Aigner A: MicroRNAs (miRNAs) in colorectal cancer: From aberrant expression towards therapy. Curr Pharm Des. 19:1242–1252. 2013. View Article : Google Scholar : PubMed/NCBI
27	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
28	Guo SJ, Zeng HX, Huang P, Wang S, Xie CH and Li SJ: MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer. Eur Rev Med Pharmacol Sci. 22:6379–6385. 2018.PubMed/NCBI
29	Long HD, Ma YS, Yang HQ, Xue SB, Liu JB, Yu F, Lv ZW, Li JY, Xie RT, Chang ZY, et al: Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma. Mol Biol Rep. 45:2615–2623. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhao C, Wang XB, Zhang YH, Zhou YM, Yin Q and Yao WC: MicroRNA-424 inhibits cell migration, invasion and epithelial-mesenchymal transition in human glioma by targeting KIF23 and functions as a novel prognostic predictor. Eur Rev Med Pharmacol Sci. 22:6369–6378. 2018.PubMed/NCBI
31	Gu X, Gong H, Shen L and Gu Q: MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. Am J Transl Res. 10:2834–2847. 2018.PubMed/NCBI
32	Li Z, Qian R, Zhang J and Shi X: MiR-218-5p targets LHFPL3 to regulate proliferation, migration and epithelial-mesenchymal transitions of human glioma cells. Biosci Rep. 39(pii): BSR201808792019. View Article : Google Scholar : PubMed/NCBI
33	Xu J, He J, Huang H, Peng R and Xi J: MicroRNA-423-3p promotes glioma growth by targeting PANX2. Oncol Lett. 16:179–188. 2018.PubMed/NCBI
34	Jiang Y, Wang X, Zhang J and Lai R: MicroRNA-599 suppresses glioma progression by targeting RAB27B. Oncol Lett. 16:1243–1252. 2018.PubMed/NCBI
35	Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, et al: Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett. 15:3273–3280. 2018.PubMed/NCBI
36	Wu K, Zhao Z, Ma J, Chen J, Peng J, Yang S and He Y: Deregulation of miR-193b affects the growth of colon cancer cells via transforming growth factor β and regulation of the SMAD3 pathway. Oncol Lett. 13:2557–2562. 2017. View Article : Google Scholar : PubMed/NCBI
37	Lu X and Lu J: The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. Clin Lab. 61:187–190. 2015. View Article : Google Scholar : PubMed/NCBI